ScottZacharyFieldsMD

Oncology • New Hyde Park, NY

Physician

Join to view full profile

Are you Dr. Fields?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 64 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
450 Lakeville Rd
Monter Cancer Center
New Hyde Park, NY 11042
Phone+1 516-734-8791

Fax+1 516-734-8662
Is this information wrong?

Summary

Dr. Scott Fields, MD is an oncologist in New Hyde Park, New York. He is currently licensed to practice medicine in New York. He is affiliated with Long Island Jewish Medical Center, North Shore University Hospital, and Glen Cove Hospital.

Education & Training

New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 1987 - 1990
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1984 - 1987
State University of New York Downstate Medical Center College of MedicineClass of 1984

Certifications & Licensure

NY State Medical License Active through 2013

Publications & Presentations

PubMed

8 citations
Quantitative measurement of alterations in DNA damage repair (DDR) pathways using single cell network profiling (SCNP)
David B. Rosen, Ling Y. Leung, Brent Louie, James Cordeiro, Andrew Conroy, Iuliana Shapira, Scott Z. Fields, Alessandra Cesano, Rachael E. Hawtin> ;Journal of Translational Medicine. 2014 Jun 25
2 citations
Prognostic significance of isolated t(8:14) in chronic lymphocytic leukemia
Jaya Ruth Asirvatham, Judith Brody, Reena Vora, Jonathan E. Kolitz, Scott Z. Fields, Chandrika Sreekantaiah, Xinmin Zhang> ;Leukemia & Lymphoma. 2014 Mar 1
2 citations
Single cell network profiling assay in bladder cancer.
Todd Covey, Manish Vira, Matt Westfall, Michael Gulrajani, Michelle Cholankeril, Zhamshid Okhunov, Helen R. Levey, Carol Marimpietri, Rachael E. Hawtin, Scott Z. Field...> ;Cytometry. Part A. 2013 Apr 1
52 citations
Activin receptor antagonists for cancer-related anemia and bone disease.
Scott Z. Fields, Shiroo Parshad, Madhurima Anne, Haralambos Raftopoulos, Mark J. Alexander, Matthew L. Sherman, Abderrahmane Laadem, Victoria Sung, Evangelos Terpos> ;Expert Opinion on Investigational Drugs. 2013 Jan 1
20 citations
A Phase I Study of 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin in Adult Patients with Refractory or Metastatic Solid Malignancies
Susanne M. Arnold, John Rinehart, Eleftheria Tsakalozou, John R. Eckardt, Scott Z. Fields, Brent J. Shelton, Philip A. DeSimone, Bryan K. Kee, Jeffrey A. Moscow, Marko...> ;Clinical Cancer Research. 2010 Jan 15
Pharmacokinetics (PK) of the highly lipophilic and blood stable camptothecin AR-67 (7-t-butyldimethylsilyl-10- hydroxycamptothecin) in adult patients with solid malign...
Leggas M, Horn J, Tsakalozou E, Moscow JA, Fields SZ, Houchins JC, Eckardt JR, DeSimone P, Kee BK, Rinehart JJ, Arnold SM> ;J. Clin. Oncol.. 2009-05-20
Clinical and pharmacokinetic (PK) findings in a phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in patients with refractory solid tumors.
Arnold SM, Horn J, Eckardt JR, Rinehart JJ, DeSimone P, Fields SZ, Kee BK, Moscow JA, Houchins JC, Leggas M> ;J. Clin. Oncol.. 2009-05-20
183 citations
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
John P. Leonard, Morton Coleman, Jamie C. Ketas, Amy Chadburn, Richard R. Furman, Michael W. Schuster, Eric J. Feldman, Michelle Ashe, Stephen J. Schuster, William A. ...> ;Clinical Cancer Research. 2004 Aug 15
10 citations
Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer.
J.L. Pujol, J. von Pawel, Salvatore Tumolo, A. Martoni, Solange Hearn, Scott Z. Fields, Glen Ross> ;Oncology. 2001 Jan 1
8 citations
Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
Saad Akhtar, Robert A. Beckman, Diane R. Mould, Edward Doyle, S Z Fields, Jonathan Wright> ;Cancer Chemotherapy and Pharmacology. 2000 Jan 1
17 citations
Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas
James P. Stevenson, Richard Scher, R Kosierowski, Stephen Fox, M. Simmonds, Kang Shen Yao, Fran Green, C. Broom, S Z Fields, J. B. Krebs, Peter J. O'Dwyer> ;European Journal of Cancer. 1998 Aug 1
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.
Gerrits CJ, Burris H, Schellens JH, Planting AS, van den Burg ME, Rodriguez GI, van Beurden V, Loos WJ, Hudson I, Fields S, Verweij J, von Hoff DD> ;Eur. J. Cancer. 1998-06-01
Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J> ;Clin. Cancer Res.. 1998-05-01
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
Eckhardt SG, Baker SD, Eckardt JR, Burke TG, Warner DL, Kuhn JG, Rodriguez G, Fields S, Thurman A, Smith L, Rothenberg ML, White L, Wissel P, Kunka R, DePee S, Littlef...> ;Clin. Cancer Res.. 1998-03-01
5 citations
Phase I study of high-dose etoposide phosphate in man.
Fields, S. Z., Budman, D. R., Young, R. R., Kreis, W., Ingram, R., Schulman, P., Cherny, R. C., Wright, J., Behr, J., Snow, C., Schacter, L. P.> ;Bone marrow transplantation. 1996 Nov 1
A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium.
Eckhardt SG, Burris HA, Eckardt JR, Weiss G, Rodriguez G, Rothenberg M, Rinaldi D, Barrington R, Kuhn JG, Masuo K, Sudo K, Atsumi R, Oguma T, Higashi L, Fields S, Smet...> ;Ann. Oncol.. 1996-07-01
12 citations
Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors
Willi Kreis, Daniel R. Budman, Vincent Vinciguerra, Kathleen Hock, Joann Baer, Richard Ingram, Lee P. Schacter, S Z Fields> ;Cancer Chemotherapy and Pharmacology. 1996 Jan 1
29 citations
Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.
Sanjeev Kaul, L N Igwemezie, David J. Stewart, S Z Fields, M Kosty, N Levithan, Ronald M. Bukowski, David R. Gandara, Glenwood D. Goss, Peter J. O'Dwyer> ;Journal of Clinical Oncology. 1995 Nov 1
18 citations
Phase I study of etoposide phosphate (Etopophos) as a 30-minute infusion on days 1, 3, and 5
S Z Fields, L N Igwemezie, Sanjeev Kaul, L P Schacter, R J Schilder, P P Litam, B S Himpler, C McAleer, J Wright, R H Barbhaiya> ;Clinical Cancer Research. 1995 Jan 1
150 citations
Subcellular Distribution of Daunorubicin in P-Glycoprotein-positive and -negative Drug-resistant Cell Lines Using Laser-assisted Confocal Microscopy
James E. Gervasoni, Scott Z. Fields, Sindu Krishna, Michael Baker, Michelle Rosado, Kalpna Thuraisamy, Alexander Hindenburg, Robert N. Taub> ;Cancer Research. 1991 Sep 15
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Glen Cove HospitalGlen Cove, New York
Long Island Jewish Medical CenterNew Hyde Park, New York
North Shore University HospitalManhasset, New York